Novasep Strengthens its Management Team with Key Appointments
News Apr 24, 2012
Novasep has announced two new managerial appointments. Jean-Claude Romain becomes the group's corporate quality director and a member of Novasep's executive committee, while Alain Lamproye joins Novasep Process, the company's biomolecules division, as director of Novasep Belgium and becomes a member of Novasep Process' management committee.
Jean-Claude Romain brings to the whole Novasep group his experience of quality and industrial production management, which he acquired at several international pharmaceutical companies (including Sanofi-Aventis, Laboratoires Galderma and Johnson & Johnson) and more recently at Novasep Process.
His appointment to the newly-created position enables Novasep to establish a global quality management function that will ensure regulatory compliance and contribute to the continuous improvement program for the company's global operations.
Alain Lamproye has held several site management and production management positions at Eurogentec and more recently within the Merck Serono group. He has taken over the management of Novasep's two Belgian sites, which are located south of Brussels.
He heads a team of more than 100 staff, that specialize in custom biopharmaceutical manufacturing and are recognized experts in the production of viruses, viral vectors, monoclonal antibodies and recombinant proteins, as well as more recently in the development of innovative compounds such as antibody-drug conjugates (ADCs).
"We are delighted with the appointment of Jean-Claude Romain as corporate quality director of Novasep," said Roger-Marc Nicoud, chairman of Novasep.
Nicoud continued, "His excellent work at Novasep Process has enabled us to continue developing our biopharmaceutical production activities. He is now going to use his experience and dynamism to improve quality control and lead the continuous improvement program at all our sites to ensure we respond to our customers' needs in an ever more effective and reliable fashion."
"The recognized experience of Alain Lamproye represents a real added value for Novasep Belgium," explains Antoine Baule, president of Novasep Process.
Baule continued, "In a fast-growing biopharmaceutical market, custom biopharmaceutical manufacturing is a strategic activity for Novasep, which we will actively continue to develop."
Children With Congenital Zika Virus Infection Face Serious Challenges as They AgeNews
The report from the CDC is the first to describe the health and developmental effects of congenital Zika virus infection in children with microcephaly through 2 years of age.READ MORE
Single-stranded Origami Technology Drives Drug Delivery Systems and Pharmaceutical Nanofactories ForwardNews
First nanotechnological approach enables the design and replication of complex single-stranded DNA and RNA origami with potential for drug delivery and nanofabrication.READ MORE